Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
10/2002
10/10/2002WO2002079221A2 Sapogenin derivatives, their synthesis and use
10/10/2002WO2002079204A1 8-thiazolyl[1,2,4]triazolo[1,5-c]pyrimidine derivative
10/10/2002WO2002079197A1 Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
10/10/2002WO2002079195A1 Substituted 2-thio-3,5-dicyano-4-phenyl-6-aminopyridines with adenosine receptor-binding activity and their use as cardiovascular preparations
10/10/2002WO2002079194A1 Ccr5 antagonists useful for treating aids
10/10/2002WO2002079189A2 Spiroisoquinoline compounds, methods for their preparation and intermediates
10/10/2002WO2002079188A1 Pyrrolidine sulfonamides
10/10/2002WO2002079170A2 Pyrimidine-2,4,6-trione derivatives, processes for their production and pharmaceutical agents containing them
10/10/2002WO2002079169A1 Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
10/10/2002WO2002079168A1 Imidazolyl derivatives useful as histamine h3 receptor ligands
10/10/2002WO2002079157A1 Aryl oxime-piperazines useful as ccr5 antagonists
10/10/2002WO2002079156A1 Novel piperidine derivatives as modulators of chemokine receptor
10/10/2002WO2002079155A1 Pyrrolidine sulfonamides
10/10/2002WO2002079154A1 Substituted carbazoles as inhibitors of spla2
10/10/2002WO2002079152A1 Cyclopropylindole derivatives as selective serotonin reuptake inhibitors
10/10/2002WO2002079146A2 Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same
10/10/2002WO2002078747A2 Pregabalin lactose conjugates
10/10/2002WO2002078745A2 Use of mglur5 antagonists in the manufacture of a medicament in the treatment of autism, mental retardation, schizophrenia
10/10/2002WO2002078744A1 Remedies for psychoneurosis
10/10/2002WO2002078731A1 Module of pd-1 interactions with its ligands
10/10/2002WO2002078730A2 Use of neublastin polypeptides for treating neuropathic pain
10/10/2002WO2002078725A1 Biologically active chloroform fraction of an extract obtained from a mangrove plant salvadora persica l
10/10/2002WO2002078707A1 Pyrrolidine sulfonamides
10/10/2002WO2002078705A1 Hsp inductor
10/10/2002WO2002078693A2 N-(2-arylethyl)benzylamines as antagonists of the 5-ht6 receptor
10/10/2002WO2002078682A2 Estrogen replacement therapy
10/10/2002WO2002078680A1 Gaba-receptor modulators for the treatment of neurodegenerative diseases of the eye
10/10/2002WO2002078643A2 Immunomodulation and effect on cell processes relating to serotonin family receptors
10/10/2002WO2002078641A2 Pyrrolidine sulfonamides
10/10/2002WO2002078629A2 Acute pharmacologic augmentation of psychotherapy with enhancers of learning or conditioning
10/10/2002WO2002078616A2 Methods for increasing serotonin levels by administering (-)-hydroxycitric acid
10/10/2002WO2002078615A2 Antioxidant nitroxides and nitrones as therapeutic agents
10/10/2002WO2002078604A2 Transdermal delivery of bioactive material
10/10/2002WO2002078602A2 Transdermal delivery of pergolide
10/10/2002WO2002062828A3 Tripeptides and tripeptide derivatives for the treatment of neurodegenerative diseases
10/10/2002WO2002062795A9 Dihydropyrazolopyridine compounds and pharmaceutical use thereof
10/10/2002WO2002060386A3 METHODS OF TREATING INFLAMMATORY AND IMMUNE DISEASES USING INHIBITORS OF IλB KINASE (IKK)
10/10/2002WO2002058636A3 Novel cannabimimetic ligands
10/10/2002WO2002057215A3 Sodium channel modulators
10/10/2002WO2002053577A3 Gabaa modulating neurosteroids
10/10/2002WO2002053516A3 N(phenylsulphonyl)glycine derivatives and their therapeutic use
10/10/2002WO2002050067A3 Pharmaceutical heterocyclic compounds
10/10/2002WO2002046373A8 Method of collecting placental stem cells
10/10/2002WO2002046178A3 Benzofuran and benzothiophene derivatives as selective cox-2 inhibitors
10/10/2002WO2002041881A3 Repinotan kit
10/10/2002WO2002036546A3 Alkynyl amides and their therapeutic applications
10/10/2002WO2002026820A3 Immunomodulatory protein derived from the yaba monkey tumor virus
10/10/2002WO2002024706A3 Water soluble rapamycin esters
10/10/2002WO2002004612A3 Drug metabolizing enzymes
10/10/2002WO2001098353A3 Secreted proteins
10/10/2002WO2001095929A3 Interferon for treatment of multiple sclerosis
10/10/2002WO2001093852A3 Method of treating pain using nalbuphine and opioid antagonists
10/10/2002WO2001078780A1 Preventives/remedies for alzheimer's disease
10/10/2002WO2001077174A3 Human transporters and ion channels
10/10/2002WO2001072728A9 Novel piperazine derivatives
10/10/2002WO2001049678A9 Substituted phenyl-piperazine derivatives, their preparation and use
10/10/2002US20020147999 Reducing neuronal tangles in alzhemier's patients; obtain human, administer modulator, monitor development of neuronal tangles in, reduction in neuronal tangles indicates modulator
10/10/2002US20020147341 Kinase inhibitor; benign prostatic hyperplasia
10/10/2002US20020147338 Pyrazolotriazines as CRF antagonists
10/10/2002US20020147336 Glucocorticoid receptor modulators
10/10/2002US20020147327 Glucocorticoid receptor protein for use in the treatment of arthritis and asthma
10/10/2002US20020147306 Peptides that modulate the interaction of B class ephrins and PDZ domains
10/10/2002US20020147238 Methods and compositions for the treatment of neuropathic pain, tinnitus, and other disorders using R(-)-ketoprofen
10/10/2002US20020147236 Controlling concentration; side effect reduction
10/10/2002US20020147234 Nitrate esters and methods of making same
10/10/2002US20020147233 Epoxyvibsanin B
10/10/2002US20020147231 Allosteric adenosine receptor modulators
10/10/2002US20020147224 2-oxo-imidazolidine-4-carboxylic acid hydroxamide compounds that inhibit matrix metalloproteinases
10/10/2002US20020147222 Brain disorders; Alzheimer's disease
10/10/2002US20020147220 Norcisapride; sleep disorders, eating disorders, irratible bowel disorders
10/10/2002US20020147206 Synergistic mixture of neurotransmitter and antidepressant
10/10/2002US20020147201 Glycyrrhizin complex
10/10/2002US20020147200 Central nervous system disorders; antiserotonine agents
10/10/2002US20020147198 Substituted arylamine derivatives and methods of use
10/10/2002US20020147194 Psychological disorders; antiserotonin agents; headache therapy
10/10/2002US20020147186 Side effect reduction
10/10/2002US20020147185 Antihypoxic agents, antiischamic agents, antiarrhythmia agents
10/10/2002US20020147138 Anticancer agents
10/10/2002US20020147137 Medical use of alpha1-acid glycoprotein (AAG) or orosomucoid
10/10/2002US20020147129 Polypeptides; nervous system, brain disorders
10/10/2002US20020146805 DNA encoding the human serine protease T
10/10/2002US20020146797 Genetically engineered enzyme for use in the treatment of cell proliferative disorders
10/10/2002US20020146759 Stress proteins and peptides and methods of use thereof
10/10/2002US20020146678 Determining preferential gene expression pattern in embryonic cells; obtain cells, monitor gene expresion products, incubate with animal growth regulators, monitor gene expresion pattern and differentiation in cells
10/10/2002US20020146469 Administering a sensory regimen which reduces or down-regulates the activity of the hypothalamus-pituitary-adrenal (HPA) axis
10/10/2002US20020146467 Herbal composition for the prevention and treatment of dementia
10/10/2002US20020146466 Solid form compositions containing an extract of a raw material as the active ingredient and process of preparing the same
10/10/2002US20020146463 Useful as food additives or in medicaments
10/10/2002US20020146461 Combining phase comprising wherein active agent, polymer, solvent and second phase; flowing emulsion through static mixers; combining outflow with extraction liquid for extracting solvent from emulsion to form microparticles
10/10/2002US20020146453 For sustained release; therapy
10/10/2002US20020146417 Administering function blocking antibody or a fragment antibody, capable of binding an epitope of VLA-1 to provide a decrease in arthritic score of about 65% or greater when compared to control antibody treated subject
10/10/2002US20020146416 Human trk receptors and neurotrophic factor inhibitors
10/10/2002US20020146414 Controlled release of non heparin-binding growth factors from heparin-containing matrices
10/10/2002US20020146408 Human haemopoietic maturation factor
10/10/2002DE10117183A1 Verwendung von substituierten Imidazo[1,2-a]-pyridinverbindungen als Arzneimittel Use of substituted imidazo [1,2-a] -pyridinverbindungen as medicaments
10/10/2002DE10116978A1 Kappa-Opiatagonisten für die Behandlung von Erkrankungen der Blase Kappa-opiate agonist for the treatment of diseases of the bladder
10/10/2002DE10116589A1 Use of creatine for reducing oxidative stress e.g. for treating aging, neurodegeneration and cancers
10/10/2002DE10115922A1 Cyclisch substituierte 2-Thio-3,5-dicyano-4-aryl-6-aminopyridine und ihre Verwendung Cyclic substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and their use
10/10/2002DE10114775A1 2-Mercapto-4,5-diarylimidazolderivate und ihre Verwendung in der Pharmazie 2-mercapto-4,5-diarylimidazolderivate and their use in the pharmaceutical
10/10/2002CA2443355A1 Central nervous system neural progenitor cell which induces synapse-forming neurons in the spinal cord
1 ... 1291 1292 1293 1294 1295 1296 1297 1298 1299 1300 1301 1302 1303 1304 1305 1306 1307 1308 1309 1310 1311 ... 1833